Members of the EGFR (Epidermal Growth Factor Receptor) family proved to be remarkably important tumour therapeutic targets. Tumours are genetic disorders caused by mutations (amplification, pont mutation) affecting directly growth factor receptors and/or their downstream signalling proteins. Molecular diagnostics are essential for the personalized therapy with the new molecular-targeted drugs acting on the EGFR family.
|Number of pages||9|
|Publication status||Published - Dec 1 2006|
ASJC Scopus subject areas